DSP-0390, an investigational new agent developed by Cambridge, Massachusetts-based Sumitomo Dainippon Pharma Oncology, is an inhibitor of emopamil-binding
/PRNewswire/ John Theurer Cancer Center at Hackensack University Medical Center, New Jersey s top ranked cancer center, according to U.S. News & World.